PALI Profile
Palisade Bio, Inc., headquartered in Carlsbad, California, operates as a clinical-stage biopharmaceutical firm dedicated to advancing innovative oral therapies targeting severe diseases linked to mucosal barrier breakdown in the gastrointestinal (GI) tract. Founded in 2005, the company focuses on discovering, developing, and commercializing therapeutic solutions that address significant unmet medical needs, particularly in surgical and GI-related conditions.
At the forefront of Palisade Bio's pipeline is LB1148, its lead therapeutic candidate. LB1148 is formulated as an oral liquid containing tranexamic acid, an enzyme inhibitor designed to mitigate abdominal adhesions in GI tissues and expedite the recovery of bowel function following surgical procedures. This innovative approach not only aims to improve patient outcomes post-surgery but also seeks to reduce healthcare costs associated with prolonged hospital stays and complications.
Palisade Bio leverages a robust research and development platform to drive its pipeline forward, focusing on advancing LB1148 through clinical trials and regulatory approvals. The company's commitment to scientific rigor and patient-centric innovation underscores its strategic efforts to bring transformative treatments to market. Additionally, Palisade Bio collaborates with leading healthcare institutions and regulatory authorities to ensure rigorous compliance with global standards and expedite the commercialization of its novel therapies.
As Palisade Bio continues to expand its portfolio and advance its pipeline, it remains dedicated to enhancing healthcare outcomes and quality of life for patients suffering from GI-related disorders. With a strong foundation in scientific excellence and a commitment to pioneering oral therapies, Palisade Bio is poised to make significant contributions to the biopharmaceutical industry, driving innovation and addressing critical medical challenges in GI healthcare.
|
